Home  /  Resource Library  /  POLATUZUMAB VEDOTIN PLUS RITUXIMAB, IFOSFAMIDE, CARBOPLATIN, ETOPOSIDE (POLA-R-ICE) VS R-ICE AS SECOND LINE TREATMENT IN LARGE B CELL LYMPHOMA (LBCL). FINAL ANALYSIS OF A RANDOMIZED PHASE 3 STUDY

POLATUZUMAB VEDOTIN PLUS RITUXIMAB, IFOSFAMIDE, CARBOPLATIN, ETOPOSIDE (POLA-R-ICE) VS R-ICE AS SECOND LINE TREATMENT IN LARGE B CELL LYMPHOMA (LBCL). FINAL ANALYSIS OF A RANDOMIZED PHASE 3 STUDY

EHA 2026